Research Clinical pathways in hip and knee arthroplasty: a prospective randomised controlled study Michelle M Dowsey, Meredith L Kilgour, Nick M Santamaria and Peter F M Choong
MJA 1999; 170: 59-62 Abstract -
Introduction -
Methods -
Results -
Discussion -
References -
Authors' details
Treatment protocols, variously known as clinical pathways,
critical pathways and care paths, that aim to streamline and
standardise management through a systematic approach so that high
quality care may be provided in a timely and cost effective
manner3,4 have been developed.
Clinical pathways describe the course of hospitalisation for
patients with a specified illness and encompass a predetermined plan
of treatment.
The use of clinical pathways is now well established and their
successes are widely reported.5-7 Joint arthroplasty is a
common and costly procedure associated with high resource use that is
frequently performed in the elderly who may have many coexisting
morbidities. These characteristics suggest that joint
arthroplasty may be a suitable procedure to incorporate into a
clinical pathway.8
As part of a "best practice" initiative in line with quality assurance
activities at St Vincent's Hospital, the hospital's Orthopaedic
Service has developed clinical pathways for hip and knee joint
arthroplasty for treating osteoarthritis which aim to maximise the
use of all available resources and minimise negative patient
outcomes, thereby improving patient care.
To this end, we report the effects of introducing clinical pathways at
our hospital on quality indicators such as mobilisation,
complication rates, discharge planning and readmission rates while
also exploring the impact on length of stay.
Patients not allocated to the pathway received "reactive" treatment
whereby the treating team responded to the will and condition of the
patient in providing postoperative care.
We calculated the sample size for this study after reviewing all hip
and knee arthroplasty patient data for 1995, which showed a mean LOS of
13 days (range, 5.8-43.3; SD, 5.3). We believed that a 20% reduction in
LOS (2.6 days) would represent a clinically significant outcome.
Therefore, we calculated that to detect a reduction of 2.6 days in LOS
at a significance level of 0.05 with a power of 0.8 would require two
groups with a minimum of 65 subjects in each group.
Our findings are summarised in Box 2. There was no significant
difference between control and pathway patients in terms of age or
weight. Although the clinical pathway group included more patients
with premorbid conditions than the control group, this difference
was not statistically significant (95% CI, - 0.03 to 0.21). Length of
stay (LOS) was significantly shorter for the pathway group than for
the control group (t = 2.585; P = 0.011). When LOS was
analysed for the subgroups of patients in each group with premorbid
conditions, this was still significantly shorter for the pathway
group than the control group (t = 3.152; P = 0.001)
despite the larger number of patients with premorbid conditions in
the pathway group.
Patients in the clinical pathway group sat out of bed and walked
earlier after surgery than control patients. Multiple linear
regression for each group showed that time to ambulation was the only
significant contributor to reduction in log LOS in the clinical
pathway group (time to ambulation -- coeff = 19.6, standard error [SE]
= 9.6, P = 0.04; time to sitting out of bed -- coeff = - 4.35, SE =
9.3, P = 0.64, R2 = 0.127). Neither time to
ambulation nor time to sit out of bed was significantly associated
with reduced log LOS in the control group (time to ambulation -- coeff =
21.05; SE = 26.28, P = 0.42; time to sit out of bed -- coeff = -
4.13, SE = 28.54, P = 0.88, R2 = 0.0251).
Patients from both the clinical pathway and control groups who
attended either the preadmission clinic (n = 122) or the
patient information seminar (n = 61) had a shorter LOS (7.22
days and 6.84 days, respectively) than patients who attended neither
(n = 36; LOS, 8.55 days). The 54 patients who attended both the
clinic and seminar had the shortest LOS at 6.6 days, and t tests
showed that the shorter LOS for these patients relative to those who
attended neither the clinic nor seminar was significant (t =
2.66; P = 0.009). Post-hoc t tests showed that the
shorter LOS for patients who had attended both preadmission clinics
and information seminars relative to those who had attended neither
was significant (t = 2.66; P = 0.009).
Box 2 shows that a greater proportion of clinical pathway patients
were discharged to their planned discharge destination than control
patients (95% CI, - 0.05 to 0.23), and that there were fewer
readmissions in clinical pathway patients (95% CI, 0.006-0.174),
although neither result was statistically significant. However,
there were significantly fewer complications in clinical pathway
patients (95% CI, 0.036-0.27). Length of stay was significantly shorter for the pathway group than
the control group despite the larger proportion of pathway patients
with premorbid conditions. This result should be interpreted
cautiously, as the small overall number of patients with premorbid
conditions meant that the test had less than optimal power (0.45).
However, we conclude that comorbidities per se should not
exclude patients from clinical pathways. Patients with comorbid
conditions may actually be better served because of the greater
fastidiousness and vigilance imposed by the daily protocol.
While our findings that there were fewer complications and
readmissions in clinical pathway patients were not significant, we
believe that given the appropriate number of subjects in future
studies both of these areas may approach significance.
We noted that reducing the length of stay did not increase the
complication rate, a finding corroborated by others.11 In addition,
the readmission rate for complications for pathway patients was
one-third that of controls. This contrasts with some studies which
have reported an inverse relationship between length of stay and
readmission rates.11 We, like other
authors,12 believe that it is a lower
quality of care and not length of stay per se that increases the
risk of unplanned readmission.
Discharge planning is an important part of the clinical pathway which
appears to be closely linked with the length of stay. Appropriate
matching of predetermined discharge destinations is a correlate of
shorter admissions. If we are able to improve on our destination
matching rate of 70%, we may be able to further reduce our length of
stay, thereby making more resources available for other patients.
Education of patients and their relatives appeared to have a positive
influence on the patients' recovery after joint arthroplasty, with
earlier mobilisation and discharge from hospital. Attending
information seminars and preadmission clinics assisted in reducing
the length of stay by almost two days. Patients and their relatives who
understand the disease and the necessary treatment may be in a better
position to assist with care and rehabilitation. Attendances for our
information seminar and preadmission clinic were 38% and 74%,
respectively, and we are endeavouring to increase these.
First introduced by the New England Medical Center, clinical
pathways are now incorporated into the management philosophy of many
hospitals worldwide.13,14 Pathways involve
input from medical, nursing, paramedical and administrative staff,
and reflect the expertise of all members of the healthcare team while
highlighting the interdependent nature of these roles in achieving
positive outcomes for patients.15
A valuable subsidiary purpose of pathways is in providing
information from which the financial cost of care may also be
derived.16 Accurate costing of
treatment is fundamental to the operation of institutions where
prospective payments are made in accordance with diagnosis-related
groups (DRGs), standardised lengths of stay and fixed reimbursement
for care. Clinical pathways thus provide an important tool for
coordinating and managing clinical resources. However, the driving
force behind clinical pathways must remain the need to improve the
quality of care and patient outcomes, and not their utility as a tool to
ensure that budgetary demands are met.
We are encouraged by our findings, which indicate substantial
improvements for patients on a clinical pathway. To our knowledge, no
other study has investigated the effect of clinical pathways on joint
arthroplasty using a contemporaneous control group.
Reprints: Professor P F M Choong, Department of
Orthopaedics, St Vincent's Hospital, 41 Victoria Parade, Fitzroy,
VIC 3065. ©MJA 1998
Home
|
Issues
|
MJA shop
| Terms of use
|
MJA Careers
|
More...
|
Contact
|
Topics
|
Search
|
RSS
| |||||||||||||||||||||||||||||||||||||||